Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04385251 · ClinicalTrials.gov registry record

International SARS-CoV-2 (COVID-19) Infection Observational Study

A clinical trial, sponsored by University of Minnesota.

Completed
Registry status
11,973
Enrollment target

NCT04385251: Completed study, sponsored by University of Minnesota.

NCT04385251 is a clinical trial that has completed, run by University of Minnesota. The registered enrollment target is 11,973 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04385251 has completed, sponsored by University of Minnesota.

COMPLETED
Registry status
11,973 participants
Enrollment target

Study Summary

The general aim of this study is to estimate the rate of disease progression for adults testing positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day follow-up period. In some locations special facilities are being built/utilized for quarantine/public health reasons for those who are SARS-CoV-2 positive. Hospitalization is defined as a stay for at least 18 hours, irrespective of reason, at a hospital or one of these special facilities after study enrollment. Secondary outcomes include participant-reported health status and change in severity of dyspnoea.

Primary Outcome

Outcome reported as the mean number of days from enrollment to hospitalization due to COVID-19.

Interventions

  • OTHER Data Collection

Trial Details

FieldValue
Enrollment Target 11,973 participants
Start Date 2020-06-18
Est. Completion 2022-01-31
University of Minnesota

966 total trials

What the finished NCT04385251 record still lists

NCT04385251 is an observational study that tracks outcomes without assigning an intervention. Its 11,973 participants enrollment target places it among the larger protocols in the corpus.

The record links to 0 conditions, and to 1 intervention - of which Data Collection is the first listed.

NCT04385251 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT04385251 about?

NCT04385251 is a clinical study titled "International SARS-CoV-2 (COVID-19) Infection Observational Study". The general aim of this study is to estimate the rate of disease progression for adults testing positive for SARS-CoV-2. The primary endpoint for this study and the basis for sample size is hospitalization or death during the 28 day follow-up period. In some locations special facilities are being bu...

What is the current status of trial NCT04385251?

This trial is currently completed. The enrollment target is 11,973 participants. The study started on 2020-06-18. Estimated completion is 2022-01-31.

What interventions are being tested in trial NCT04385251?

The interventions under investigation include: Data Collection (OTHER).

Who is sponsoring clinical trial NCT04385251?

This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01772771 · 12,000 participants

    Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

  • NCT04937868 · 12,000 participants

    Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients

  • NCT06059963 · 12,000 participants

    A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation

  • NCT06273618 · 12,000 participants · NA

    iLookOut Micro-learning to Improve Knowledge Retention

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04385251, the US trial registry maintained by the National Library of Medicine. NCT04385251 (large enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.